martes, 30 de octubre de 2018

Cholic acid for primary bile acid synthesis defects: a life-saving therapy allowing a favorable outcome in adulthood | Orphanet Journal of Rare Diseases | Full Text

Cholic acid for primary bile acid synthesis defects: a life-saving therapy allowing a favorable outcome in adulthood | Orphanet Journal of Rare Diseases | Full Text

Orphanet Journal of Rare Diseases



Cholic acid for primary bile acid synthesis defects: a life-saving therapy allowing a favorable outcome in adulthood

  • ,
  • ,
  • ,
  • ,
  • ,
  • ,
  • ,
  • ,
  • ,
  •  and
  • Email authorView ORCID ID profile
Contributed equally
Orphanet Journal of Rare Diseases201813:190
  • Received: 19 January 2018
  • Accepted: 24 September 2018
  • Published: 

Abstract

Background

Oral cholic acid (CA) replacement has been shown to be an effective therapy in children with primary bile acid synthesis defects, which are rare and severe genetic liver diseases. To date there has been no report of the effects of this therapy in children reaching adulthood. The aim of the study was to evaluate the long-term effectiveness and safety of CA therapy.

Methods

Fifteen patients with either 3β-hydroxy-Δ5-C27-steroid oxidoreductase (3β-HSD) (n = 13) or Δ4–3-oxosteroid 5β-reductase (Δ4–3-oxo-R) (n = 2) deficiency confirmed by mass spectrometry and gene sequencing received oral CA and were followed prospectively.

Results

The median age at last follow-up and the median time of follow-up with treatment were 24.3 years (range: 15.3–37.2) and 21.4 years (range: 14.6–24.1), respectively. At last evaluation, physical examination findings and blood laboratory test results were normal in all patients. Liver sonograms were normal in most patients. Mean daily CA dose was 6.9 mg/kg of body weight. Mass spectrometry analysis of urine showed that excretion of the atypical metabolites remained low or traces in amount with CA therapy. Liver fibrosis scored in liver biopsies or assessed by elastography in 14 patients, after 10 to 24 years with CA therapy, showed a marked improvement with disappearance of cirrhosis (median score < F1; range: F0-F2). CA was well tolerated in all patients, including five women having 10 uneventful pregnancies during treatment.

Conclusions

Oral CA therapy is a safe and effective long-term treatment of 3β-HSD and Δ4–3-oxo-R deficiencies and allows affected children to reach adulthood in good health condition without the need for a liver transplantation.

Keywords

  • Bile acid
  • Genetic cholestasis
  • AKR1D1
  • HSD3B7

1 comentario:

  1. Excellently written article, if only all blogger offered the same level of content as you, the internet would be a much better place. Please keep it up!.Great tips, I would like to join your blog anyway.Waiting for some more review.Thank you
    Failed Back Surgery
    Hip Pain Treatments
    Chronic Headache Causes
    Joint Pain Frankfort
    Musculoskeletal Pain Frankfort
    Neck Pain Frankfort
    Pelvic Pain Frankfort

    ResponderEliminar